High Levels of Serum Cystatin C, Uric Acid, and Lactate Dehydrogenase Before Chemotherapy Affect Lung Cancer Prognosis

Elevated concentrations of uric acid (UA), lactate dehydrogenase (LDH), and serum cystatin C (Cys C) prior to chemotherapy may affect the prognosis of small-cell lung cancer (SCLC), according to a study published in Oncology Letters.

In this study, researchers assessed 205 patients with SCLC using data procured from medical records.  They used the receiver operating characteristic curve to determine the optimal cut-off values of Cys C, UA, and LDH. The Kaplan-Meier method was used for survival analysis, while Cox proportional hazard modeling was used for univariate and multivariate analyses.

According to the results, the survival curves showed that both progression-free survival (PFS) and overall survival (OS) times were shorter in patients with high levels of Cys C, UA, and LDH prior to chemotherapy. Moreover, univariate and multivariate analyses indicated that LDH concentration prior to chemotherapy may be an independent prognostic factor for both PFS and OS in patients with SCLC, while Cys C concentration may be an independent prognostic factor for PFS in patients with SCLC, the researchers noted. Overall, the results showed that concentrations of Cys C, UA, and LDH prior to chemotherapy were linked with disease progression in SCLC.

“Taken together, the results of the present study suggest that high concentrations of LDH and Cys C prior to chemotherapy may indicate rapid disease progression, thus it is important to focus on the progression and recurrence of the disease. High LDH concentration may also indicate a shorter survival time,” the researchers concluded.